Publications by authors named "Daniel D Fraughen"

Claim this Profile
S
Seasonal Changes in Circulating Alpha-1 Antitrypsin Are Altered by Sex and Genetic Deficiency.
Emma J Leacy, Daniel D Fraughen, Ronan C Heeney, Michelle Casey, Mark Sherlock

Am J Respir Crit Care Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimising bronchoalveolar lavage: lessons from alpha-1 antitrypsin deficiency.
Malcolm Herron, Suzanne Roche, Daniel D Fraughen, Ronan C Heeney, Lasya Kanchi

Thorax· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delayed Tuberculosis Paradoxical Reaction Associated with Tumor Necrosis Factor Inhibitors.
Suzanne M Roche, Ciara Ottewill, Rachel Mulpeter, Kevin Brown, Conor Grant, Daniel D Fraughen

Am J Respir Crit Care Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Chan: Identification of Alpha-1 Antitrypsin-Deficient Subjects with Normal Spirometry Who May Benefit from Alpha-1 Antitrypsin Replacement.
Daniel D Fraughen, Auyon J Ghosh, Tomás P Carroll, Noel G McElvaney

Am J Respir Crit Care Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpha-1 Antitrypsin Augmentation and the Liver Phenotype of Adults With Alpha-1 Antitrypsin Deficiency (Genotype Pi∗ZZ).
Malin Fromme, Karim Hamesch, Carolin V Schneider, Mattias Mandorfer, Monica Pons, Daniel D Fraughen

Clin Gastroenterol Hepatol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Reactogenicity of COVID-19 Vaccination in Severe Alpha-1 Antitrypsin Deficiency.
Oliver J McElvaney, Brian Cleary, Daniel D Fraughen, Geraldine Kelly, Oisin F McElvaney

Chronic Obstr Pulm Dis· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline-A Multinational Registry Analysis.
Daniel D Fraughen, Auyon J Ghosh, Brian D Hobbs, Georg-Christian Funk, Tobias Meischl

Am J Respir Crit Care Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpha-1 Antitrypsin Deficiency and Smoking Cessation: Tackling the Burden of COPD One Test at a Time?
Suzanne M Roche, Tomás P Carroll, Daniel D Fraughen, Noel G McElvaney

Chest· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpha-1 antitrypsin deficiency: current therapy and emerging targets.
Oisín F McElvaney, Daniel D Fraughen, Oliver J McElvaney, Tomás P Carroll, Noel G McElvaney

Expert Rev Respir Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19.
Oliver J McElvaney, Natalie L McEvoy, Fiona Boland, Oisín F McElvaney, Grace Hogan, Daniel D Fraughen

Med· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attitudes Towards Vaccination for Coronavirus Disease 2019 in Patients with Severe Alpha-1 Antitrypsin Deficiency.
Oliver J McElvaney, Brian Cleary, Daniel D Fraughen, Geraldine Kelly, Mark P Murphy

Chronic Obstr Pulm Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis